- Home
- SYRE vs OCS Comparison
SYRE vs OCS Comparison
Compare SYRE & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- OCS
- Stock Information
- Founded
- SYRE 2013
- OCS 2003
- Country
- SYRE United States
- OCS Switzerland
- Employees
- SYRE N/A
- OCS N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- OCS Health Care
- Exchange
- SYRE Nasdaq
- OCS Nasdaq
- Market Cap
- SYRE 1.1B
- OCS 869.8M
- IPO Year
- SYRE 2016
- OCS N/A
- Fundamental
- Price
- SYRE $16.23
- OCS $19.00
- Analyst Decision
- SYRE Strong Buy
- OCS Strong Buy
- Analyst Count
- SYRE 6
- OCS 4
- Target Price
- SYRE $57.60
- OCS $36.50
- AVG Volume (30 Days)
- SYRE 681.2K
- OCS 31.4K
- Earning Date
- SYRE 11-06-2025
- OCS 11-06-2025
- Dividend Yield
- SYRE N/A
- OCS N/A
- EPS Growth
- SYRE N/A
- OCS N/A
- EPS
- SYRE N/A
- OCS N/A
- Revenue
- SYRE N/A
- OCS $960,668.00
- Revenue This Year
- SYRE N/A
- OCS $36.75
- Revenue Next Year
- SYRE N/A
- OCS $1,261.53
- P/E Ratio
- SYRE N/A
- OCS N/A
- Revenue Growth
- SYRE N/A
- OCS N/A
- 52 Week Low
- SYRE $10.91
- OCS $13.60
- 52 Week High
- SYRE $40.26
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- SYRE 52.04
- OCS 67.52
- Support Level
- SYRE $15.87
- OCS $17.26
- Resistance Level
- SYRE $17.18
- OCS $17.80
- Average True Range (ATR)
- SYRE 0.88
- OCS 0.48
- MACD
- SYRE 0.08
- OCS 0.17
- Stochastic Oscillator
- SYRE 70.65
- OCS 82.99
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.